{"analyses":[{"ciLowerLimit":"79.5","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"101.5","groupDescription":"Avelumab was the Reference treatment and Avelumab + PLD was the Test treatment","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Geometric Mean Ratio (Test/Reference, %)","paramValue":"90"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"43","value":"231.6"},{"groupId":"OG001","spread":"71","value":"207.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"description":"Cmax was defined as maximum observed serum concentration, and can be observed directly from data.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Avelumab 10 milligram (mg)/kilogram (kg) given as a 1-hour intravenous (IV) infusion every 2 weeks (Q2W) in 4-week cycles.","id":"OG000","title":"Avelumab"},{"description":"Avelumab 10 mg/kg given as a 1-hour IV Q2W in 4-week cycles + pegylated liposomal doxorubicin (PLD) 40 mg/square meter given as a 1-hour IV infusion every 4 weeks (Q4W) in 4-week cycles.","id":"OG001","title":"Avelumab + PLD"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK parameter analysis set was defined as participants in the safety analysis set who had at least 1 post-dose concentration measurement above the LLQ for avelumab.","reportingStatus":"POSTED","timeFrame":"At postdose (end of infusion, 1H) on Cycle 2 Day 1","title":"Serum Maximum Concentration (Cmax) For Avelumab Following Cycle 2 Day 1 PLD Dose","type":"SECONDARY","unitOfMeasure":"mcg/mL"}